ANCA-Associated Vasculitis, Anti-GBM Disease, and Lupus Nephritis
By:
Stephen P. McAdooCentre for Inflammatory Disease, London, United Kingdom and
Imperial College Healthcare NHS Trust, London, United Kingdom

Search for other papers by Stephen P. McAdoo in
Current site
Google Scholar
PubMed
Close
and
Charles D. PuseyCentre for Inflammatory Disease, London, United Kingdom and
Imperial College Healthcare NHS Trust, London, United Kingdom

Search for other papers by Charles D. Pusey in
Current site
Google Scholar
PubMed
Close
  • Collapse
  • Expand
  • 1

    Jennette JC, Falk RJ: Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 10: 463473, 2014 PubMed

  • 2

    Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, et al.: ANCA-associated vasculitis. Nat Rev Dis Primers 6: 71, 2020 PubMed

  • 3

    Jennette JC: Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17: 603606, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4

    Rovin BH, Adler SG, Barratt J, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100: S1S276, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5

    Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al.: 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73: 13661383, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6

    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187192, 1994 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7

    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al.: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65: 111, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8

    Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, et al.: The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33: 10651067, 1990 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9

    Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, et al.: ACR/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clin Exp Nephrol 17: 619621, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10

    Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al.; DCVAS Investigators: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 81: 315320, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11

    Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al.; DCVAS Study Group: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 81: 309314, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12

    Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al.; DCVAS INVESTIGATORS: 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 81: 321326, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13

    Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin L, et al.: Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 13: 683692, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14

    Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, et al.: 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev 19: 102618, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15

    O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S, Coughlan AM, et al.: Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol 27: 29062916, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16

    Moran SM, Monach PA, Zgaga L, Cuthbertson D, Carette S, Khalidi NA, et al.: Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 35: 283291, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17

    Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al.: Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21: 16281636, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18

    van Daalen EE, Wester Trejo MAC, Göçeroğlu A, Ferrario F, Joh K, Noël LH, et al.: Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol 15: 11031111, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19

    Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M, et al.: Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 94: 11771188, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20

    Moura MC, Fervenza FC, Specks U, Sethi S: Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 37: 17101721, 2022

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21

    Boudhabhay I, Delestre F, Coutance G, Gnemmi V, Quemeneur T, Vandenbussche C, et al.: Reappraisal of renal arteritis in ANCA-associated vasculitis: Clinical characteristics, pathology, and outcome. J Am Soc Nephrol 32: 23622374, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22

    Chapman GB, Farrah TE, Chapman FA, Pugh D, Bellamy COC, Lahiri R, et al.: Utility of interval kidney biopsy in ANCA-associated vasculitis. Rheumatology (Oxford) 61: 19661974, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23

    Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D, Harper L, Jayne D, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group: BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53: 23062309, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24

    Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al.: EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75: 15831594, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25

    De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 24612469, 2005 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26

    Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al.; EUVAS investigators: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis 71: 955960, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27

    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221232, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28

    Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211220, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29

    Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al.; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis 78: 399405, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30

    Tuin J, Stassen PM, Bogdan DI, Broekroelofs J, van Paassen P, Cohen Tervaert JW, et al.: Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: Randomized, controlled trial. Clin J Am Soc Nephrol 14: 10211028, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31

    Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, et al.: Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis. Am J Kidney Dis 57: 566574, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32

    Walters GD, Willis NS, Cooper TE, Craig JC: Interventions for renal vasculitis in adults. Cochrane Database Syst Rev 2020: CD003232, 2020

    • Search Google Scholar
    • Export Citation
  • 33

    Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, et al.; PEXIVAS Investigators: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382: 622631, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34

    Kronbichler A, Shin JI, Wang CS, Szpirt WM, Segelmark M, Tesar V: Plasma exchange in ANCA-associated vasculitis: The pro position. Nephrol Dial Transplant 36: 227231, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35

    Specks U, Fussner LA, Cartin-Ceba R, Casal Moura M, Zand L, Fervenza FC: Plasma exchange for the management of ANCA-associated vasculitis: the con position. Nephrol Dial Transplant 36: 231236, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36

    Walsh M, Collister D, Zeng L, Merkel PA, Pusey CD, Guyatt G, et al.; Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis BMJ Rapid Recommendations Group: The effects of plasma exchange in patients with ANCA-associated vasculitis: An updated systematic review and meta-analysis. BMJ 376: 064604, 2022 PubMed

    • Search Google Scholar
    • Export Citation
  • 37

    Zeng L, Walsh M, Guyatt GH, Siemieniuk RAC, Collister D, Booth M, et al.: Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: A clinical practice guideline. BMJ 376: 064597, 2022 PubMed

    • Search Google Scholar
    • Export Citation
  • 38

    Nezam D, Porcher R, Grolleau F, Morel P, Titeca-Beauport D, Faguer S, et al.; French Vasculitis Study Group: Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges. J Am Soc Nephrol 33: 628637, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39

    Casal Moura M, Soler MJ, Sethi S, Fervenza FC, Specks U: Kidney histopathology in ANCA-associated vasculitides treated with plasma exchange. J Am Soc Nephrol 33: 12231224, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40

    Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al.; LoVAS Collaborators: Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial. JAMA 325: 21782187, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41

    Chen M, Jayne DRW, Zhao MH: Complement in ANCA-associated vasculitis: Mechanisms and implications for management. Nat Rev Nephrol 13: 359367, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42

    Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al.; CLEAR Study Group: Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28: 27562767, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43

    Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group: Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384: 599609, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44

    Dhaun N, McAdoo SP: The changing role of glucocorticoids in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 101: 201204, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45

    Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al.; European Vasculitis Study Group: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 21802188, 2007 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46

    Casal Moura M, Irazabal MV, Eirin A, Zand L, Sethi S, Borah BJ, et al.: Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease. J Am Soc Nephrol 31: 26882704, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47

    Gulati K, Edwards H, Prendecki M, Cairns TD, Condon M, Galliford J, et al.: Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 100: 13161324, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48

    McAdoo SP, Medjeral-Thomas N, Gopaluni S, Tanna A, Mansfield N, Galliford J, et al.: Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis [published correction appears in Nehrol Dial Transplant 33: 899, 2018]. Nephrol Dial Transplant 34: 6373, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49

    Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J, Hamour S, et al.: A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis [published correction appears in Rheumatology (Oxford) 58: 373, 2019]. Rheumatology (Oxford) 58: 260268, 2019 PubMed

    • Search Google Scholar
    • Export Citation
  • 50

    Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 139274, 2012

    • Search Google Scholar
    • Export Citation
  • 51

    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, et al.; European Vasculitis Study Group: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 3644, 2003 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52

    Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al.; European Vasculitis Study Group (EUVAS): Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA 304: 23812388, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 53

    Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, et al.; European Vasculitis Society: Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76: 16621668, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 54

    Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al.; French Vasculitis Study Group: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371: 17711780, 2014 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 55

    Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, et al.; French Vasculitis Study Group: Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77: 11501156, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 56

    Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, Huart A, et al.; French Vasculitis Study Group: Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77: 11431149, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 57

    Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, et al.; French Vasculitis Study Group: Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 173: 179187, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58

    van Dam LS, Dirikgil E, Bredewold EW, Ray A, Bakker JA, van Kooten C, et al.: Proteinase-3-anti-neutrophil cytoplasmic antibodies (PR3-ANCAs) predict relapses in ANCA-associated vasculitis patients after rituximab. Nephrol Dial Transplant 36: 14081417, 2021

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59

    Tieu J, Smith R, Basu N, Brogan P, D’Cruz D, Dhaun N, et al.: Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines. Rheumatology (Oxford) 59: 2432, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 60

    Wallace ZS, Fu X, Harkness T, Stone JH, Zhang Y, Choi H: All-cause and cause-specific mortality in ANCA-associated vasculitis: Overall and according to ANCA type. Rheumatology (Oxford) 59: 23082315, 2019

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 61

    Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubieta JA: Mortality in ANCA-associated vasculitis: A meta-analysis of observational studies. Ann Rheum Dis 76: 15661574, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62

    Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al.; European Vasculitis Study Group: Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70: 488494, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63

    McGovern D, Williams SP, Parsons K, Farrah TE, Gallacher PJ, Miller-Hodges E, et al.: Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology (Oxford) 59: 10761083, 2020

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 64

    Waki D, Nishimura K, Tokumasu H, Kadoba K, Mukoyama H, Saito R, et al.: Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study. Medicine (Baltimore) 99: 19173, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 65

    Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, et al.: Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol 10: 11281135, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66

    McAdoo SP, Pusey CD: Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 12: 11621172, 2017 PubMed

  • 67

    Canney M, O’Hara PV, McEvoy CM, Medani S, Connaughton DM, Abdalla AA, et al.: Spatial and temporal clustering of anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 11: 13921399, 2016

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68

    Gu QH, Xie LJ, Jia XY, Ma R, Liao Y-H, Cui Z, et al.: Fever and prodromal infections in anti-glomerular basement membrane disease. Nephrology (Carlton) 23: 476482, 2018

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 69

    Prendecki M, Clarke C, Cairns T, Cook T, Roufosse C, Thomas D, et al.: Anti-glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int 98: 780781, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 70

    Prema KSJ, Kurien A: Incidence of anti-glomerular basement membrane disease during the COVID-19 pandemic. Clin Kidney J 15: 180181, 2021 PubMed

  • 71

    Sebastian R, Arunachalam J, Rajendran M: Temporal clustering of antiglomerular basement membrane disease in COVID-19 pandemic: A case series. Int J Nephrol Renovasc Dis 14: 393398, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 72

    Ooi JD, Chang J, O’Sullivan KM, Pedchenko V, Hudson BG, Vandenbark AA, et al.: The HLA-DRB1*15:01-restricted Goodpasture’s T cell epitope induces GN. J Am Soc Nephrol 24: 419431, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 73

    Ooi JD, Petersen J, Tan YH, Huynh M, Willett ZJ, Ramarathinam SH, et al.: Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 545: 243247, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 74

    Pokidysheva EN, Seeger H, Pedchenko V, Chetyrkin S, Bergmann C, Abrahamson D, et al.: Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture’s and Alport diseases. J Biol Chem 296: 100590, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75

    Boudko SP, Bauer R, Chetyrkin SV, Ivanov S, Smith J, Voziyan PA, et al.: Collagen IVα345 dysfunction in glomerular basement membrane diseases. II. Crystal structure of the α345 hexamer. J Biol Chem 296: 100591, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 76

    Pedchenko V, Boudko SP, Barber M, Mikhailova T, Saus J, Harmange JC, et al.: Collagen IVα345 dysfunction in glomerular basement membrane diseases. III. A functional framework for α345 hexamer assembly. J Biol Chem 296: 100592, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 77

    Huart A, Josse AG, Chauveau D, Korach JM, Heshmati F, Bauvin E, et al.; French Society of Hemapheresis: Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun 73: 2429, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78

    Marques C, Carvelli J, Biard L, Faguer S, Provôt F, Matignon M, et al.: Prognostic factors in anti-glomerular basement membrane disease: A multicenter study of 119 patients. Front Immunol 10: 1665, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 79

    Jia XY, Xu HY, Jia XY, Cui Z, Zhao MH: Predictors of kidney outcomes of anti-glomerular basement membrane disease in a large Chinese cohort. Am J Nephrol 53: 397406, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 80

    van Daalen EE, Jennette JC, McAdoo SP, Pusey CD, Alba MA, Poulton CJ, et al.: Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol 13: 6372, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 81

    Yang R, Otten MA, Hellmark T, Collin M, Björck L, Zhao MH, et al.: Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant 25: 24792486, 2010 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 82

    Soveri I, Mölne J, Uhlin F, Nilsson T, Kjellman C, Sonesson E, et al.: The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int 96: 12341238, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 83

    Uhlin F, Szpirt W, Kronbichler A, Bruchfeld A, Soveri I, Rostaing L, et al.: Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: An open-label phase 2a study. J Am Soc Nephrol 33: 829838, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 84

    McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, et al.: Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 92: 693702, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 85

    McCall AS, Bhave G, Pedchenko V, Hess J, Free M, Little DJ, et al.: Inhibitory anti-peroxidasin antibodies in pulmonary-renal syndromes. J Am Soc Nephrol 29: 26192625, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 86

    Shen CR, Jia XY, Luo W, Olaru F, Cui Z, Zhao MH, et al.: Laminin-521 is a novel target of autoantibodies associated with lung hemorrhage in anti-GBM disease. J Am Soc Nephrol 32: 18871897, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 87

    Nasr SH, Collins AB, Alexander MP, Schraith DF, Herrera Hernandez L, Fidler ME, et al.: The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int 89: 897908, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 88

    Vankalakunti M, Nada R, Kumar A, Patro K, Ramakrishnan S, Rangarajan D: Circulating monoclonal IgG1-kappa antibodies causing anti-glomerular basement membrane nephritis. Indian J Nephrol 27: 327329, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 89

    Shen CR, Jia XY, Cui Z, Yu XJ, Zhao MH: Clinical-pathological features and outcome of atypical anti-glomerular basement membrane disease in a large single cohort. Front Immunol 11: 2035, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 90

    Rosales IA, Colvin RB: Glomerular disease with idiopathic linear immunoglobulin deposition: a rose by any other name would be atypical. Kidney Int 89: 750752, 2016 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 91

    Salama AD, Dougan T, Levy JB, Cook HT, Morgan SH, Naudeer S, et al.: Goodpasture’s disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 39: 11621167, 2002 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 92

    Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al.; American College of Rheumatology: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64: 797808, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 93

    Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, et al.; British Society for Rheumatology Standards, Audit and Guidelines Working Group: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford) 57: e1e45, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 94

    Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al.: 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79: 713723, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 95

    Almaani S, Meara A, Rovin BH: Update on lupus nephritis. Clin J Am Soc Nephrol 12: 825835, 2017 PubMed

  • 96

    Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C: Lupus nephritis. Nat Rev Dis Primers 6: 7, 2020 PubMed

  • 97

    Maningding E, Dall'Era M, Trupin L, Murphy LB, Yazdany J: Racial/ethnic differences in prevalence of and time to onset of SLE manifestations: The California Lupus Surveillance Project (CLSP). Arthritis Care Res (Hoboken) 72: 622629, 2020

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 98

    Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, et al.: Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 77: 13181325, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 99

    Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al.: Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93: 789796, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 100

    Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, et al.: Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 32: 13381344, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 101

    De Rosa M, Azzato F, Toblli JE, De Rosa G, Fuentes F, Nagaraja HN, et al.: A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 94: 788794, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 102

    Turner-Stokes T, Wilson HR, Morreale M, Nunes A, Cairns T, Cook HT, et al.: Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int 92: 12231231, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 103

    Bourse Chalvon N, Orquevaux P, Giusti D, Gatouillat G, Tabary T, Tonye Libyh M, et al.: Absence of anti-glomerular basement membrane antibodies in 200 patients with systemic lupus erythematosus with or without lupus nephritis: Results of the GOODLUPUS Study. Front Immunol 11: 597863, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 104

    Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, et al.: Exostosin 1/exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 30: 11231136, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 105

    Mackay M, Dall’Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, et al.: Establishing surrogate kidney end points for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 71: 411419, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 106

    Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al.: Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med 162: 1826, 2015 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 107

    Zhang H, Liu Z, Zhou M, Liu Z, Chen J, Xing C, et al.: Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 28: 36713678, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 108

    Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, et al.; AURA-LV Study Group: A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95: 219231, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 109

    Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al.: Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397: 20702080, 2021 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 110

    Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al.: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72: 12801286, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 111

    Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, et al.: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24: 37173723, 2009 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 112

    Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al.; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 12151226, 2012 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 113

    Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al.: Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13: 15021509, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 114

    Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A, et al.; Groupe Coopératif sur le Lupus Rénal: Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore) 96: e7429, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 115

    Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al.: B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81: 100107, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 116

    Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al.: Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum 65: 23682379, 2013 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 117

    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377: 721731, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 118

    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al.; BLISS-76 Study Group: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63: 39183930, 2011 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 119

    Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al.: Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383: 11171128, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 120

    Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, et al.: A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101: 403413, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 121

    Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, et al.: The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91: 4554, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 122

    Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EW, et al.: Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol 1: 208219, 2019

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 123

    Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators: Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382: 211221, 2020 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 124

    Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al.: Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 81: 496506, 2022 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 125

    Felten R, Sagez F, Gavand PE, Martin T, Korganow AS, Sordet C, et al.: 10 most important contemporary challenges in the management of SLE. Lupus Sci Med 6: 000303, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 330 330 243
Full Text Views 486 486 390
PDF Downloads 601 601 495